Author:
Janiri Delfina,Sampogna Gaia,Albert Umberto,Caraci Filippo,Martinotti Giovanni,Serafini Gianluca,Tortorella Alfonso,Zuddas Alessandro,Fiorillo Andrea,Sani Gabriele
Abstract
Abstract
Background
Lithium is one of the most consistently effective treatment for mood disorders. However, patients may show a high level of heterogeneity in treatment response across the lifespan. In particular, the benefits of lithium use may vary in special clinical conditions. The aim of this study was to test this hypothesis by conducting an umbrella review on the efficacy and safety of lithium in childhood and adolescence, peripartum and old age.
Methods
We applied the Preferred Reporting Items for Systematic Reviews and Meta-analyses criteria (PRISMA) to identify systematic reviews/meta-analyses on the efficacy and/or safety of lithium in mood disorders in special clinical conditions: (i) childhood and adolescence; (ii) peripartum (pregnancy, postpartum and lactation); (iii) old age. The Risk of Bias Assessment Tool for Systematic Reviews (ROBIS) tool was used to assess the risk of bias. Overlap in primary studies across systematic reviews was calculated through the Corrected Covered Area (CCA).
Results
We included 20 independent studies, for a total of 8209 individuals treated with lithium. Regarding paediatric age, efficacy and safety results suggested that lithium may be superior to placebo in bipolar disorders (BD) and not associated with serious adverse events. Nevertheless, primary available data are very limited. Efficacy in paediatric major depressive disorder (MDD) is not clear. During peripartum, lithium use was superior to non-lithium in preventing mood episodes and it was associated with low risk of congenital anomalies and with normal child neurodevelopment. Regarding old age, limited evidence supported lithium as an effective treatment in BD and resistant MDD; low doses should be used in this population. Systematic reviews on paediatric age showed the lowest risk of bias (80% of the studies at low risk). The CCA range of included studies was 13–47%.
Conclusions
This umbrella review supports the use of lithium across the lifespan, including special clinical condition. Nevertheless, more studies with increased methodological homogeneity are needed.
Funder
The publication work has been realized thank to an unconditional support of Angelini Pharma.
Publisher
Springer Science and Business Media LLC
Subject
Biological Psychiatry,Psychiatry and Mental health
Reference67 articles.
1. Akiskal HS. New insights into the nature and heterogeneity of mood disorders. J Clin Psychiatry. 1989;50(6–10):11–2.
2. Amerio A, Ossola P, Scagnelli F, Odone A, Allinovi M, Cavalli A, et al. Safety and efficacy of lithium in children and adolescents: a systematic review in bipolar illness. Eur Psychiatry. 2018;54(85):97.
3. Arnold I, Dehning J, Grunze A, Hausmann A. Old age bipolar disorder-epidemiology aetiology and treatment. Medicina. 2021;57:6.
4. Baldessarini RJ, Tondo L, Vázquez GH. Pharmacological treatment of adult bipolar disorder. Mol Psychiatry. 2019;24(2):198–217.
5. Bersani G, Quartini A, Zullo D, Iannitelli A. Potential neuroprotective effect of lithium in bipolar patients evaluated by neuropsychological assessment: preliminary results. Hum Psychopharmacol Clin Exp. 2016;31(1):19–28. https://doi.org/10.1002/hup.2510.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献